Status:
UNKNOWN
SBRT With S1 Combined With Endostar in the Treatment of Lung Cancer
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Mianyang Central Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Radiotherapy Side Effect
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Human recombinant endostatin preclinical studies have shown that the drug can inhibit endothelial cell proliferation, angiogenesis and tumor growth, still can directly induce lung cancer cell apoptosi...
Detailed Description
In this study, the investigatorse enrolled patients with advanced lung squamous cell carcinoma to explore the safety and efficacy of sequential local radiotherapy combined with endodontic therapy.Plan...
Eligibility Criteria
Inclusion
- Lung squamous cell carcinoma was confirmed by histopathology or cytopathology;
- Meet AJCC(8th edition, 2018) lung cancer stage IV standard;
- Lesions requiring SBRT;
- Measurable lesions must have at least one evaluable lesion judged according to RECIST 1.1 standard, i.e., the longest diameter is at least 20mm);
- Age \>=18 years old;
- KPS \> = 70;
- Life expectancy of at least 3 months;
- Hematology, liver and kidney function and cardiopulmonary function can tolerate radiotherapy and chemotherapy.
Exclusion
- Lung adenocarcinoma or small cell lung cancer;
- Previous immunotherapy;
- Patients at risk of bleeding;
- Patients with any other malignant tumor before or now
- Patients diagnosed with esophagotracheal fistula,uncontrolled pleural effusion,pericardial effusion requiring repeated drainage,unhealed wounds,active gastric ulcers or fractures
- Patients suffering from poorly controlled heart disease or clinical symptoms, such as NYHA grade II or above cardiac dysfunction;unstable angina pectoris;Myocardial infarction occurred within 1 year;supraventricular or ventricular arrhythmia needs treatment or intervention;
- Patients with known central nervous system metastases.
- Patients with clinically suspected central nervous system metastasis must undergo enhanced CT or MRI within 28 days prior to randomization to exclude central nervous system metastasis.
- Pregnant or breastfeeding women;Women and men who are likely to become pregnant but do not want to use appropriate contraception;
- Other circumstances in which the investigator decides not to participate in this study.
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04274270
Start Date
April 1 2020
End Date
January 30 2023
Last Update
March 19 2020
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100000
2
The fifth medical center of PLA general hospital
Beijing, Beijing Municipality, China, 100000
3
Liuzhou Worker's Hospital
Liuchow, Guangxi, China
4
Guangxi ruikang hospital
Nanning, Guangxi, China, 530000